Skip to main content
Premium Trial:

Request an Annual Quote

Ten RNAi-Related Patent Applications Published by the USPTO

Premium

Title: Methods and Means for Producing Efficient Silencing Construct Using Recombinational Cloning

Number: 20050160490

Filed: Jan. 12, 2005

Lead Inventor: Christopher Helliwell, Commonwealth Scientific and Industrial Research Organization

According to its abstract, the patent application covers "methods and means … for producing chimeric nucleic acid constructs capable of producing dsRNA for silencing target nucleic acid sequences of interest using recombinational cloning."


Title: RNA Interference-Mediated Inhibition of Polycomb Group Protein EZH2 Gene Expression Using Short Interfering Nucleic Acid

Number: 20050159382

Filed: Aug. 19, 2004

Lead Inventor: James McSwiggen, Sirna Therapeutics

According to the patent application's abstract, the invention "relates to compounds, compositions, and methods useful for modulating polycomb group protein EZH2 gene expression using short interfering nucleic acid molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of polycomb group protein EZH2 gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid, short interfering RNA, double-stranded RNA, microRNA, and short hairpin RNA molecules and methods used to modulate the expression of polycomb group protein EZH2 genes, such as EZH2."


Title: RNA Interference-Mediated Inhibition of Chromosome Translocation Gene Expression Using Short Interfering Nucleic Acid

Number: 20050159381

Filed: Aug. 20, 2004

Lead Inventor: James McSwiggen, Sirna Therapeutics

According to the patent application's abstract, the invention "relates to compounds, compositions, and methods useful for modulating chromosomal translocation gene expression using short interfering nucleic acid molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of chromosomal translocation gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid, short interfering RNA, double-stranded RNA, microRNA, and short hairpin RNA molecules and methods used to modulate the expression of BCR-ABL, ERG, EWS-ERG, TEL-AML1, EWS-FLI1, TLS-FUS, PAX3-FKHR, and/or AML1-ETO fusion genes."


Title: RNA Interference-Mediated Inhibition of Angiopoietin Gene Expression Using Short Interfering Nucleic Acid

Number: 20050159380

Filed: Aug. 19, 2004

Lead Inventor: Roberto Guerciolini, Sirna Therapeutics

According to the patent application's abstract, the invention "relates to compounds, compositions, and methods useful for modulating angiopoietin gene expression using short interfering nucleic acid molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of angiopoietin gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid, short interfering RNA, double-stranded RNA, microRNA, and short hairpin RNA molecules and methods used to modulate the expression of angiopoietin genes, such as angiopoietin-1 (Ang-1), angiopoietin-2 (Ang-2), angiopoietin-3 (Ang-3), and angiopoietin-4 (Ang-4)."


Title: RNA Interference-Mediated Inhibition of Gastric Inhibitory Polypeptide and Gastric Inhibitory Polypeptide Receptor Gene Expression Using Short Interfering Nucleic Acid

Number: 20050159379

Filed: Aug. 11, 2004

Lead Inventor: James McSwiggen, Sirna Therapeutics

According to the patent application's abstract, the invention "relates to compounds, compositions, and methods useful for modulating gastric inhibitory polypeptide (GIP) and/or gastric inhibitory polypeptide receptor (GIPr) gene expression using short interfering nucleic acid molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of gastric inhibitory polypeptide (GIP) and/or gastric inhibitory polypeptide receptor (GIPr) gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid, short interfering RNA, double-stranded RNA, microRNA, and short hairpin RNA molecules and methods used to modulate the expression of gastric inhibitory polypeptide (GIP) and/or gastric inhibitory polypeptide receptor (GIPr) genes."


Title: RNA Interference-Mediated Inhibition of Myc and/or Myb Gene Expression Using Short Interfering Nucleic Acid

Number: 20050159378

Filed: Aug. 11, 2004

Lead Inventor: James McSwiggen, Sirna Therapeutics

According to the patent application's abstract, the invention "relates to compounds, compositions, and methods useful for modulating Myc and/or Myb gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of Myc and/or Myb gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA, double-stranded RNA, microRNA, and short hairpin RNA molecules and methods used to modulate the expression of Myc and/or Myb (e.g., c-Myc, N-Myc, L-Myc, c-Myb, a-Myb, b-Myb, and v-Myb) genes. The small nucleic acid molecules are useful in the treatment of cancer and other diseases and disorders."


Title: RNA Interference-Mediated Inhibition [of] 5-Alpha Reductase and Androgen Receptor Gene Expression Using Short Interfering Nucleic Acid

Number: 20050159376

Filed: May 12, 2004

Lead Inventor: James McSwiggen, Sirna Therapeutics

According to the patent application's abstract, the invention "relates to compounds, compositions, and methods useful for modulating 5-alpha reductase (SRD5A-1, SRD5A-2) and androgen receptor gene expression using short interfering nucleic acid molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of 5-alpha reductase and androgen receptor gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid, short interfering RNA, double-stranded RNA, microRNA, and short hairpin RNA molecules and methods used to modulate the expression of 5-alpha reductase and androgen receptor genes."


Title: Methods for Eliminating or Reducing the Expression of Genes in a Filamentous Fungal Strain

Number: 20050158844

Filed: Dec. 9, 2004

Lead Inventor: Howard Brody, Novozymes Biotech

The invention, the patent application's abstract states, "relates to methods for reducing or eliminating the expression of a target gene in a filamentous fungal strain, comprising: (a) inserting into the genome of the filamentous fungal strain a double-stranded transcribable nucleic acid construct comprising a first nucleotide sequence comprising a promoter operably linked to a homologous coding region of the target gene and a second nucleotide sequence comprising the homologous coding region, or a portion thereof, of the target gene, wherein the first and second nucleotide sequences are complementary to each other and the second nucleotide sequence is in reverse orientation relative to the first nucleotide sequence; and (b) inducing production of an interfering RNA encoded by the double-stranded transcribable nucleic acid construct by cultivating the filamentous fungal strain under conditions conducive for production of the interfering RNA; wherein the interfering RNA interacts with RNA transcripts of the target gene to reduce or eliminate expression of the target gene," the abstract states. "The … invention also relates to the filamentous fungal strains and to methods of producing a biological substance of interest in such filamentous fungal strains."


Title: RNA Interference-Mediated Inhibition of Proliferating Cell Nuclear Antigen Gene Expression Using Short Interfering Nucleic Acid

Number: 20050158735

Filed: Aug. 11, 2004

Lead Inventor: James McSwiggen, Sirna Therapeutics

According to the patent application's abstract, the invention "relates to compounds, compositions, and methods useful for modulating PCNA gene expression using short interfering nucleic acid molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of PCNA gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid, short interfering RNA, double-stranded RNA, microRNA, and short hairpin RNA molecules and methods used to modulate the expression of PCNA genes. The small nucleic acid molecules are useful in the treatment of cancer or restenosis or other proliferative diseases, disorders, or conditions."


Title: Method and Carrier Complexes for Delivering Molecules to Cells

Number: 20050158373

Filed: May 3, 2004

Lead Inventor: Hazel Szeto, Cornell University

"The invention relates to carrier complexes and methods for delivering molecules to cells," according to the patent application's abstract. "The carrier complexes comprise a molecule and an aromatic cationic peptide in accordance with the invention. In one embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a carrier complex. In another embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a molecule and an aromatic cationic peptide."

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.